Neurocrine Biosciences is executing a robust growth trajectory, with revenue accelerating to $959.0M in 2026Q2, a 39.5% year-over-year increase, driven by strong commercial execution and a high-margin product portfolio. The company's gross margin consistently ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 39.5% year-over-year in 2026Q2, reaching $959.0M, with gross margins consistently above 97.6% and operating margin expanding from 4.1% in 2025Q1 to 15.8% in 2026Q2.
Neurocrine Biosciences presented a retrospective case series of CRENESSITY for patients with classic congenital adrenal hyperplasia, showcasing potential therapeutic benefits.
MarketBeat and other platforms provide stock analysis, price targets, and earnings estimates for NBIX, indicating strong institutional interest.
The presentation of CRENESSITY at ENDO 2026 highlights Neurocrine's ongoing pipeline development and potential for future growth.
Trailing total returns as of 9/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $1.39-15.8% vs $1.65 | $959M+7.6% vs $891M |
Q2 2026 May 5, 2026 | $1.94+59.0% vs $1.22 | $815M+6.0% vs $768M |
Q1 2026 Feb 11, 2026 | $1.88+4.4% vs $1.80 | $806M+1.9% vs $790M |
Q4 2025 Oct 28, 2025 | $2.04+29.1% vs $1.58 | $795M-1.5% vs $807M |
Neurocrine Biosciences NASDAQ: NBIX outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company's efforts to diversify beyond its largest product, INGREZZA.
Integrated Wealth Concepts LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 41.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,041 shares of the company's stock after selling 5,703 shares during the period. Integrated Wealth Concepts
Corient Private Wealth LP increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 21.4% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,680 shares of the company's stock after purchasing an additional 9,645 shares during
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark NBIX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Neurocrine Biosciences, Inc. (NBIX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $138.94 | $13.97B | 29.75 | 21.45% | 16.73% | 16.38% | — | |
| $20.66 | $1.52B | 6.26 | 18.52% | 80.56% | 30.03% | — | |
| $22.18 | $3.8B | 9.69 | 11.87% | 33.42% | 32.39% | — | |
| $62.28 | $5.17B | 8.01 | 114.51% | -3.8% | — | — | |
| $14.77 | $1.45B | -2.53 | 20.13% | -81.79% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
Neurocrine Biosciences, Inc. (NBIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Neurocrine Biosciences, Inc. (NBIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
May 28, 2026·SEC
May 18, 2026·SEC
Get notified when NBIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Neurocrine Biosciences, Inc. (NBIX) stock FAQ — growth, dividends, profitability & financials explained
Neurocrine Biosciences, Inc. (NBIX) reported $3.37B in revenue for fiscal year 2025. This represents a 17472% increase from $19.2M in 1996.
Neurocrine Biosciences, Inc. (NBIX) grew revenue by 21.4% over the past year. This is strong growth.
Yes, Neurocrine Biosciences, Inc. (NBIX) is profitable, generating $705.5M in net income for fiscal year 2025 (16.7% net margin).
Neurocrine Biosciences, Inc. (NBIX) has a return on equity (ROE) of 16.4%. This is reasonable for most industries.
Neurocrine Biosciences, Inc. (NBIX) generated $870.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
